About Aegera Therapeutics
Aegera Therapeutics is a company based in Montreal (Canada) founded in 2000 was acquired by PharmaScience in May 2011.. Aegera Therapeutics has raised $37.9 million across 5 funding rounds from investors including Desjardins, PharmaScience and BDC. Aegera Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Montreal, Canada
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$37.9 M (USD)
in 5 rounds
-
Latest Funding Round
$6.53 M (USD), Debt – Conventional
Sep 23, 2009
-
Investors
Desjardins
& 11 more
-
Employee Count
Employee Count
-
Acquired by
PharmaScience
(May 27, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Aegera Therapeutics
Aegera Therapeutics has successfully raised a total of $37.9M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $6.53 million completed in September 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Debt – Conventional — $6.5M
-
First Round
First Round
(20 Feb 2002)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2009 | Amount | Debt – Conventional - Aegera Therapeutics | Valuation |
investors |
|
| Nov, 2006 | Amount | Debt – Conventional - Aegera Therapeutics | Valuation |
investors |
|
| Oct, 2006 | Amount | Series C - Aegera Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aegera Therapeutics
Aegera Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Desjardins, PharmaScience and BDC. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity buyouts are targeted by the investment firm.
|
Founded Year | Domain | Location | |
|
Stage-agnostic sector-agnostic VC firm investing in Canada and the US
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aegera Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aegera Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aegera Therapeutics Comparisons
Competitors of Aegera Therapeutics
Aegera Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aegera Therapeutics
Frequently Asked Questions about Aegera Therapeutics
When was Aegera Therapeutics founded?
Aegera Therapeutics was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Where is Aegera Therapeutics located?
Aegera Therapeutics is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Is Aegera Therapeutics a funded company?
Aegera Therapeutics is a funded company, having raised a total of $37.9M across 5 funding rounds to date. The company's 1st funding round was a Series C of $12.2M, raised on Feb 20, 2002.
What does Aegera Therapeutics do?
Aegera Therapeutics, part of Pharmascience, is focused on developing targeted therapeutics to address major unmet medical needs. Aegera focuses on preclinical and early-stage clinical development through integration of in-house medicinal chemistry, biochemistry, cell biology, pharmacokinetics and in vivo pharmacologyefficacy. Aegera has one oncology program in clinical development and several preclinical programs. HGS1029 is a small molecule pan-IAP inhibitor that has demonstrated very promising preclinical activity across a broad range of cancers. A license and collaboration agreement was completed in December 2007 with Human Genome Sciences and HGS1029 is currently progressing in Phase 1 - solid tumor study. Aegera has several preclinical stage programs targeting key proteins involved in oncology and autoimmuneinflammatory diseases, including a small molecule Brutons tyrosine kinase (Btk) inhibitor program.
Who are the top competitors of Aegera Therapeutics?
Aegera Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Aegera Therapeutics's investors?
Aegera Therapeutics has 12 investors. Key investors include Desjardins, PharmaScience, BDC, Invest Quebec, and VenGrowth VG Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.